Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis

被引:3
|
作者
Solis-Tarazona, Luis [1 ]
Raket, Lars Lau [2 ]
Cabello-Murgui, Javier [1 ]
Reddam, Salma [1 ]
Navarro-Quevedo, Silvia [3 ]
Gil-Perotin, Sara [1 ,4 ,5 ]
机构
[1] Inst Invest Sanitaria La Fe, Res Grp Immunotherapy & Biomodels Autoimmun, Valencia, Spain
[2] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Lund, Sweden
[3] Hosp Univ & Politecn La Fe, Neurol, Valencia, Spain
[4] Hosp Univ & Politecn La Fe, Multiple Sclerosis Unit, Neurol, Valencia, Spain
[5] Inst Salud Carlos III, Consorcio Ctr Invest Biomed Red CIBER, CB06-05-1131, Madrid, Spain
来源
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
关键词
multiple sclerosis; biomarker; relapse; Z-score; RMS; CEREBROSPINAL-FLUID; DISABILITY;
D O I
10.3389/fneur.2024.1354431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The assessment of serum neurofilament light chain (sNFL) has emerged as a diagnostic and prognostic tool in monitoring multiple sclerosis (MS). However, the application of periodic measurement in daily practice remains unclear.Objective To evaluate the predictive value of individual sNFL levels in determining disease activity in patients with relapsing MS (RMS).Methods In this two-year prospective study, 129 RMS patients underwent quarterly sNFL assessments and annual MRI scans. The study analyzed the correlation between individual NFL levels and past, current, and future disease activity. Group-level Z-scores were employed as a comparative measure.Results Among the 37 participants, a total of 61 episodes of disease activity were observed. sNFL levels proved valuable in distinct ways; they were confirmatory of previous and current clinical and/or radiological activity and demonstrated a high negative predictive value for future 90 days activity. Interestingly, Z-scores marginally outperformed sNFL levels in terms of predictive accuracy, indicating the potential for alternative approaches in disease activity assessment. In our cohort, sNFL cut-offs of 10.8 pg./mL (sensitivity 27%, specificity 90%) and 14.3 pg./mL (sensitivity 15%, specificity 95%) correctly identified 7 and 4 out of 26 cases of radiological activity within 90 days, respectively, with 14 and 15% false negatives. When using lower cut-off values, individuals with sNFL levels below 5 pg/mL (with a sensitivity of 92%, specificity of 25%, and negative predictive value of 94%) were less likely to experience radiological activity within the next 3 months.Conclusion Individual sNFL levels may potentially confirm prior or current disease activity and predict short-term future radiological activity in RMS. These findings underscore its periodic measurement as a valuable tool in RMS management and decision-making, enhancing the precision of clinical evaluation in routine practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Serum neurofilament light chain predicts disease activity in relapsing remitting multiple sclerosis
    Varhaug, K.
    Barro, C.
    Bjornevik, K.
    Torkildsen, O.
    Wergeland, S.
    Bindoff, L. A.
    Kuhle, J.
    Vedeler, C. A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 589 - 590
  • [2] Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity and Treatment Response in Patients with Progressive and Relapsing Multiple Sclerosis
    Pedrini, Marzena
    Kaskow, Belinda
    Trend, Stephanie
    Carroll, William
    Walters, Susan
    Maceski, Aleksandra
    Kuhle, Jens
    Kermode, Allan
    NEUROLOGY, 2023, 100 (17)
  • [3] Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis
    Uher, Tomas
    Schaedelin, Sabine
    Benova, Barbora
    Barro, Christian
    Bergsland, Niels
    Dwyer, Michael
    Tyblova, Michaela
    Kucerova, Karolina
    Benkert, Pascal
    Michalak, Zuzanna
    Leppert, David
    Naegelin, Yvonne
    Krasensky, Jan
    Seidl, Zdenek
    Vaneckova, Manuela
    Havrdova, Eva Kubala
    Kappos, Ludwig
    Zivadinov, Robert
    Horakova, Dana
    Kuhle, Jens
    Kalincik, Tomas
    NEUROLOGY, 2019, 92 (15)
  • [4] Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis
    Engel, Sinah
    Protopapa, Maria
    Steffen, Falk
    Papanastasiou, Vakis
    Nicolaou, Christoforos
    Protopapas, Michalis
    Zipp, Frauke
    Bittner, Stefan
    Luessi, Felix
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [5] Serum neurofilament light chain levels as multiple sclerosis biomarker
    Abd-ElHady, Mohamed E.
    Hashish, Ehab
    Yassine, Imane
    Anani, Maha
    Negm, Mohamed
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2024, 28 (02) : 28 - 32
  • [6] Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet
    Oh, Unsong
    Woolbright, Emma
    Lehner-Gulotta, Diana
    Coleman, Rachael
    Conaway, Mark
    Goldman, Myla D.
    Brenton, J. Nicholas
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 73
  • [7] Prognostic Value of Baseline Serum Neurofilament Light Chain Levels in People With Relapsing Multiple Sclerosis by Prior Treatment Status and DMT Type
    Bittner, Stefan
    Cross, Anne H.
    Pardo, Gabriel
    Zamvil, Scott S.
    Bhatt, Alit
    Wei, Wenjia
    Boer, Ibolya
    Thouvenot, Eric
    Ziemssen, Tjalf
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 306 - 306
  • [8] Serum Neurofilament Light Chain Levels as a Biomarker of Disease Activity, Progression and Treatment Response in Patients with Multiple Sclerosis
    Fabis-Pedrini, Marzena
    Kaskow, Belinda
    Trend, Stephanie
    Carroll, William
    Walters, Sue
    Maceski, Aleksandra
    Kuhle, Jens
    Kermode, Allan
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP2 - NP2
  • [9] Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
    Bjornevik, Kjetil
    Munger, Kassandra L.
    Cortese, Marianna
    Barro, Christian
    Healy, Brian C.
    Niebuhr, David W.
    Scher, Ann I.
    Kuhle, Jens
    Ascherio, Alberto
    JAMA NEUROLOGY, 2020, 77 (01) : 58 - 64
  • [10] Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis
    Sen, Monokesh K. K.
    Hossain, Md Jakir
    Mahns, David A. A.
    Brew, Bruce J.
    JOURNAL OF NEUROLOGY, 2023, 270 (04) : 1908 - 1930